


(Abstract P208 figure 1, ($p=0.018$)). In parallel, reactive oxygen species generation increased with each BMI category ($p=0.026$). Furthermore, the eosinophil count dropped significantly with increasing BMI in the asthma patients ($p=0.045$).



Abstract P208 Figure 1 Whole blood neutrophil count in controls vs asthmatic individuals according to BMI category ($p=0.022$).

Conclusion Preliminary data from this study suggests that obesity is associated with systemic inflammation resulting in increasing levels of circulating neutrophils and that this is more marked in asthmatics than controls. This is in keeping with recent work showing increased neutrophils locally in the sputum of obese asthmatics. Our findings could explain the reduced inhaled corticosteroid efficacy observed in this asthma phenotype.

COPD: exacerbations, survival and end of life care

P209 RISK FACTORS FOR RESPIRATORY EXACERBATIONS IN THE BOLD STUDY

doi:10.1136/thoraxjnl-2011-201054c.209

¹L Gnatiuc, ¹S Coton, ²S Buist, ¹B Kato, ³P Mejza, ¹P Burney. ¹Imperial College London, London, UK; ²Oregon Health & Sciences University, Portland, USA; ³Jagiellonian University School of Medicine, Cracow, Poland

Background Exacerbations are important clinical events related to long-term outcomes in asthma and Chronic Obstructive Pulmonary Disease (COPD). However their determinants are not fully understood (Hurst *et al*, 2010). We used the BOLD data to assess the prevalence and risk factors for respiratory exacerbations among population-based samples of adults aged 40+ across 18 BOLD sites.

Methods Exacerbations were defined as at least one reported episode of breathing problems that interfered with usual daily activities or led to missing work in the previous 12 months. Multiple logistic regressions were used to estimate the effects of potential risk factors for reported exacerbations: medical history, FVC, occupational, biomass and smoking exposures, education, age and sex. All effects were mutually adjusted and estimated using probability weights to allow for the sampling design. Regression models were fitted separately for each centre before pooling results across centres using

random effects meta-analysis. Heterogeneity was summarised using the I^2 statistic.

Results The 12-month prevalence of reported exacerbations ranged from 1.9% in Guangzhou, China to 14.2% in Lexington, USA, it was higher in subjects with spirometrically defined COPD as compared to subjects without spirometric COPD (14.4% vs 4.2%, $p<0.0001$) and in low and middle income countries as compared to high income countries (7.9% vs 4.9%, $p<0.0001$). Exacerbations were associated with doctor diagnosed asthma, COPD stage 1+, chronic bronchitis, increase in MMRC dyspnoea score, current exposures to biomass and dusty jobs and history of TB (see Abstract P209 table 1). Similar trends for overall effect estimates were obtained for low and middle income countries and high income countries with and without biomass exposure information. The variation in reported exacerbations across sites is unlikely to be due to variation in the influence of different risk factors between sites except for COPD stages 1 and 2 ($I^2=44\%$, $p=0.03$), biomass exposure ($I^2=57\%$, $p=0.01$) and reported history of TB ($I^2=65.2\%$, $p=0.001$).

Abstract P209 Table 1 Risk factors for exacerbations (meta-analysis)

	Overall Adjusted OR* (95% CI)	Overall I^2 (%)	p Value for overall I^2
Female	1.45 (1.00 to 2.09)	0.0	0.8
Age	0.97 (0.95 to 0.99)	42.1	0.03
Education level	0.95 (0.78 to 1.15)	18.6	0.2
Pack years smoked—per 10 increase	0.90 (0.73 to 1.12)	24.7	0.2
Ex-smoker	1.19 (0.81 to 1.74)	0.0	0.8
Current-smoker	1.37 (0.85 to 2.21)	0.0	0.5
COPD—mild and moderate	2.55 (1.70 to 3.82)	44.0	0.03
COPD—severe and very severe	3.62 (2.11 to 6.18)	0.0	0.6
Doctor Diagnosed Asthma	4.92 (3.77 to 6.42)	0.0	0.9
MMRC Dyspnoea—increased severity	2.14 (1.86 to 2.46)	31.7	0.1
Chronic bronchitis	3.03 (1.97 to 4.66)	14.4	0.3
Post BD FVC	0.90 (0.68 to 1.19)	40.4	0.04
Current biomass exposure	2.67 (1.25 to 5.68)	57.0	0.01
Current dusty job	1.60 (1.16 to 2.22)	15.5	0.3
CVD	1.28 (0.98 to 1.68)	0.0	0.9
Diabetes	1.52 (0.94 to 2.48)	35.3	0.08
Tuberculosis	2.76 (1.10 to 6.91)	65.2	0.001
Childhood respiratory disease	1.52 (0.92 to 2.51)	0.0	0.6
Family history of COPD or asthma	1.35 (1.00 to 1.83)	11.4	0.3

*Mutual adjustment for all the risk factors in the table and height and weight, weighted for survey design.

Conclusion Respiratory exacerbations commonly occur in those with normal ventilatory function. Exacerbations are associated with severity of COPD, doctor diagnosed asthma, and environmental exposure to biomass and workplace dust. Chronic cough and phlegm and a diagnosis of emphysema are also associated with an increased risk for exacerbation in people with and without irreversible airway obstruction.

P210 WHICH SYMPTOMS PROMPT PATIENTS WITH AN EXACERBATION OF COPD TO PERSEVERE, SELF-TREAT OR SEEK CARE? A COMPARISON WITH HEALTH PROFESSIONALS

doi:10.1136/thoraxjnl-2011-201054c.210

¹J S Wilson, ²J J Sittlington, ²E McCrum-Gardner, ³F Kee, ¹J S Elborn. ¹Belfast Health & Social Care Trust, Belfast, Northern Ireland; ²University of Ulster, Jordanstown, Northern Ireland; ³Queen's University, Belfast, Northern Ireland

Introduction and Objectives Exacerbations of Chronic Obstructive Pulmonary Disease are a major cause of morbidity and mortality. Despite the increased healthcare utilisation involved in treatment,

little is known about how patients recognise an exacerbation. This study aims to identify the signs and symptoms that prompt patients to seek medical attention and also to identify which signs and symptoms health professionals expect patients to consider.

Methods A Factorial Survey was used to create clinical vignettes describing a variety of signs and symptoms of an exacerbation. A total of 30 patients with Chronic Obstructive Pulmonary Disease (mean %FEV₁ 38.9) and 47 health professionals (14 GPs, 19 Specialist Nurses and 15 Respiratory Consultants/Registrars) completed a unique random set of vignettes. A total of 600 patient and 960 health professional vignettes were analysed using multiple regression analysis.

Results There are substantial variations in the symptoms which patients regard as important prompts for action, compared to health professional expectations. Patients rely mainly on the colour and purulence of sputum ($p<0.001$) as a cue for all possible actions, whereas health professionals expected patients to consider a variety of symptoms.

Conclusion Many symptoms health professionals regard as important are not used to by patients to guide their decisions. As there is increasing focus on patients self-managing their disease, health professionals should exploit the symptoms patients already rely on rather than trying to change their behaviour.

P211 EXACERBATION FREQUENCY AND MAINTENANCE TREATMENT OF COPD IN UK CLINICAL PRACTICE

doi:10.1136/thoraxjnl-2011-201054c.211

¹M Thomas, ²A Radwan, ³C Stonham, ⁴S Marshall. ¹University of Aberdeen, Aberdeen, UK; ²Novartis Pharmaceuticals, Frimley, UK; ³Minchinhampton Surgery, Stroud, UK; ⁴pH Associates, Marlow, UK


Introduction and Objectives COPD exacerbations are associated with high morbidity, mortality and costs. Prevention of exacerbations is recommended as a key goal of COPD management. Pharmacotherapy shown to reduce exacerbation frequency includes long acting beta agonists (LABA), long acting antimuscarinics (LAMA) and inhaled corticosteroids (ICS). There have been suggestions of a "frequent exacerbator" phenotype across severity.

Methods Retrospective observational study of 511 patients with COPD diagnosed during or before 2007. Three years' data per patient on exacerbation frequency, therapies and resource use were collected by trained researchers from routine medical records in 10 general practices in England. COPD severity was defined as: very severe (FEV₁ <30% predicted, n=52), severe (30–49%, n=145) and moderate (50–79%, n=314). Exacerbation frequency was annualised and stratified by: 0/year ("non-exacerbators"), >0<3/year and =3/year ("frequent exacerbators").

Results Mean (SD) annual exacerbation frequency: 1.1 (1.1) in moderate, 1.7 (1.6) in severe and 2.2 (2.0) in very severe COPD. 69 (14%) were frequent exacerbators and 97 (19%) were non-exacerbators. The proportion of frequent exacerbators increased with severity (9% moderate, 19% severe, 29% very severe). 14% did not receive any LABA, 25% any LAMA and 12% any ICS medication during the 3-year study period. "Triple therapy" with all three classes was received by only 67% of the frequent exacerbators. The percentage of patients with zero exacerbations/year fell as severity increased (25% moderate, 11% severe, 8% very severe). 61% received a LABA and/or LAMA with ICS (56% moderate, 75% severe and 100% very severe). 32% did not receive ICS during the study period (35% moderate, 25% severe and 0% very severe). The median number of primary care visits was 1.33 for patients with 0, 2.67 for >0<3 and 6.67 for =3 exacerbations/year.

Conclusions The "frequent exacerbator" phenotype occurs in patients of all levels of severity in community practice in the UK. Health resource use is high in frequent exacerbators. These patients

frequently do not receive optimum therapy. The exacerbation history can potentially guide maintenance treatment of patients at all levels of COPD severity.



Abstract P211 Figure 1 Distribution of number of COPD exacerbations per year by severity of disease.

P212 THE DECAF SCORE: PREDICTING IN-HOSPITAL MORTALITY IN ACUTE EXACERBATIONS OF COPD

doi:10.1136/thoraxjnl-2011-201054c.212

¹J Steer, ²G J Gibson, ¹S C Bourke. ¹Department of Respiratory Medicine, North Tyneside General Hospital, Northumbria Healthcare NHS Foundation Trust, North Shields, UK; ²Newcastle University, Newcastle-upon-Tyne, UK

Background Despite the often poor outcome of patients hospitalised with acute exacerbations of COPD (AECOPD), it is difficult accurately to identify those at high risk of mortality. To aid prognostication in AECOPD, we have developed a simple, easily memorable and effective tool, based on clinical data available shortly after admission.

Methods Consecutive patients hospitalised with AECOPD were recruited, with clinical and demographic data collected at admission. In-hospital mortality data were collected from hospital records. Variables were dichotomised and the strongest independent predictors of mortality were identified by logistic regression analysis. Tool performance was assessed using ROC curve analysis.

Results 920 patients were recruited: mean (SD) age was 73.1 (10.0) years, with 53.9% female; most had severe airflow obstruction (FEV₁ 43.6 (17.2) % predicted) and were of normal weight (BMI 24.6 (6.3) kg/m²). 32.5% of patients had coexistent consolidation and 199 (21.6%) received assisted ventilation during their hospital stay. 96 (10.4%) patients died in-hospital. In descending order of strength, the factors independently predicting mortality were: the extended MRC Dyspnoea Scale (eMRCD)¹; coexistent radiographic consolidation; eosinopenia (<0.05×10⁹/l); pH <7.3; atrial fibrillation; cough effectiveness; albumin <36 g/dl; age=80 years; cerebrovascular disease; and BMI <18.5 kg/m². The strongest five variables were selected to form the DECAF (Dyspnoea, Eosinopenia, Consolidation, Acidaemia, atrial Fibrillation) score (Abstract P212

Abstract P212 Table 1 DECAF score and in-hospital mortality

DECAF score	n	In-hospital mortality, %	Sensitivity*	Specificity*
0	201	0.5	1	0
1	291	2.1	0.99	0.24
2	226	8.4	0.93	0.59
3	125	24	0.73	0.84
4	57	45.6	0.42	0.96
5	20	70	0.15	0.99
6	0	NA	NA	NA

*For DECAF score ≥ that stated.